BioMed Realty Earns Positive Outlook On Its Investment Grade Corporate Credit Rating From Moody's

BioMed Realty Earns Positive Outlook On Its Investment Grade Corporate Credit
                             Rating From Moody's

PR Newswire

SAN DIEGO, March 31, 2014

SAN DIEGO, March 31, 2014 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE:
BMR) today announced that its rating outlook on its investment grade corporate
credit rating from Moody's Investors Service has been revised to positive from
stable. The company previously received a positive outlook on its investment
grade corporate credit rating from Standard & Poor's Rating Services in June

According to Greg N. Lubushkin, Chief Financial Officer of BioMed Realty, "We
are very pleased with the positive outlook from Moody's which reflects the
sustained, systematic enhancement of our credit quality since we became the
first life science real estate investment trust to receive an investment grade
corporate credit rating in 2010. In addition, the recent Moody's and S&P
actions validate our steady approach to growing our industry-leading
portfolio, as well as our proven track record of executing a sound, long-term
capital strategy which enables us to better serve the life science communities
in the United States and United Kingdom."

About BioMed Realty Trust

BioMed Realty, with its trusted expertise and valuable relationships, delivers
optimal real estate solutions for biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed Realty owns or has interests in
properties comprising approximately 16.3 million rentable square feet.
Additional information is available at Follow us on
Twitter @biomedrealty.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions, developments and other
investments, and the ability to refinance indebtedness as it comes due;
failure to maintain the company's investment grade credit ratings with the
ratings agencies; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully; reductions in asset valuations and related
impairment charges; risks and uncertainties affecting property development and
construction; risks associated with tax credits, grants and other subsidies to
fund development activities; risks associated with downturns in foreign,
domestic and local economies, changes in interest rates and foreign currency
exchange rates, and volatility in the securities markets; ownership of
properties outside of the United States that subject the company to different
and potentially greater risks than those associated with the company's
domestic operations; risks associated with the company's investments in loans,
including borrower defaults and potential principal losses; potential
liability for uninsured losses and environmental contamination; risks
associated with the company's potential failure to qualify as a REIT under the
Internal Revenue Code of 1986, as amended, and possible adverse changes in tax
and environmental laws; and risks associated with the company's dependence on
key personnel whose continued service is not guaranteed. For a further list
and description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The
company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE BioMed Realty Trust, Inc.

Contact: Jim Cullinan, Vice President, Marketing, (858) 207-2072,
Press spacebar to pause and continue. Press esc to stop.